Ian Frank, MD
Professor of Medicine at the Hospital of the University of Pennsylvania
Director, Antiretroviral Clinical Research, Infectious Diseases Division, University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania, Infectious Diseases Division
Member, Executive Committee, Penn Center for AIDS Research
Director, Clinical/Therapeutics Program, Penn Center for AIDS Research
Associate Chief, Infectious Diseases Division
Department: Medicine
Contact information
502 Johnson Pavilion
3610 Hamilton Walk 6073
Philadelphia, PA 19104-6073
3610 Hamilton Walk 6073
Philadelphia, PA 19104-6073
Office: 215-964-1077
Fax: 215-662-7899
Fax: 215-662-7899
Education:
AB (Russian)
Dartmouth College, 1977.
MD (Medicine)
Dartmouth Medical School, 1980.
Permanent linkAB (Russian)
Dartmouth College, 1977.
MD (Medicine)
Dartmouth Medical School, 1980.
Description of Research Expertise
HIV infection, COVID-19 disease, Vaccinology, Prevention, Treatment, PathogenesisDescription of Clinical Expertise
HIV and AIDS, Viral hepatitis, COVID-19, Sexually Transmitted InfectionsSelected Publications
Anderson EM, Li SH, Awofolaju M, Eilola T, Goodwin E, Bolton MJ, Gouma S, Manzoni TB, Hicks P, Goel RR, Painter MM, Apostolidis SA, Mathew D, Dunbar D, Fiore D, Brock A, Weaver J, Millar JS, DerOhannessian S; UPenn COVID Processing Unit, Greenplate AR, Frank I, Rader DJ, Wherry EJ, Bates P, Hensley SE.: SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations. Cell Rep 41: 111496, Oct 2022.Schuster DJ, Karuna S, Brackett C, Wesley MS, Li SS, Eisel N, Tenney D, Hilliard S, Yates NL, Heptinstall JR, Williams LD, Shen X, Rolfe R, Cabello R, Zhang L, Sawant S, Hu J, Randhawa AK, Hyrien O, Hural JA, Corey L, Frank I, Tomaras GD, Seaton KE.: Lower SARS-CoV-2 specific humoral immunity in People Living with HIV-1 recovered from non-hospitalized COVID-19. JCI Insight Sep 2022.
Vakili S, Paneru B, Guerrier CM, Miller J, Baumrin E, Forrestel A, Lynn K, Frank I, Lo Re V 3rd, Collman RG, Hill DA.: Altered adipose tissue macrophage populations in people with HIV on integrase inhibitor-containing antiretroviral therapy. AIDS 36: 1493-1500, Sep 2022.
Mayer KH, Yuhas K, Amico KR, Wilkin T, Landovitz RJ, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Cottle LM, Marcus C, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Magnus M, Farley JE, Liu AY, Frank I, Ho K, Santana J, Stekler JD, Chen YQ, McCauley M, Gulick RM; HPTN 069/ACTG 5305 Study Team.: Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). AIDS Behav Jun 2022.
Blumberg EA, Noll JH, Tebas P, Fraietta JA, Frank I, Marshall A, Chew A, Veloso EA, Carulli A, Rogal W, Gaymon AL, Schmidt AH, Barnette T, Jurek R, Martins R, Hudson BM, Chavda K, Bailey CM, Church SE, Noorchashm H, Hwang WT, June CH, Hexner EO.: A phase I trial of cyclosporine for hospitalized patients with COVID-19. JCI Insight 7: e155682, Jun 2022.
Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Van Dromme I, Spiessens B, Vingerhoets J, Custers J, Scheper G, Robb ML, Treanor J, Ryser MF, Barouch DH, Swann E, Marovich MA, Neuzil KM, Corey L, Stoddard J, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group.: Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N Engl J Med 386: 847-860, Mar 2022.
Apostolidis SA, Sarkar A, Giannini HM, Goel RR, Mathew D, Suzuki A, Baxter AE, Greenplate AR, Alanio C, Abdel-Hakeem M, Oldridge DA, Giles JR, Wu JE, Chen Z, Huang YJ, Belman J, Pattekar A, Manne S, Kuthuru O, Dougherty J, Weiderhold B, Weisman AR, Ittner CAG, Gouma S, Dunbar D, Frank I, Huang AC, Vella LA; UPenn COVID Processing Unit, Reilly JP, Hensley SE, Rauova L, Zhao L, Meyer NJ, Poncz M, Abrams CS, Wherry EJ.: Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19. Front Immunol 13: 834988, Mar 2022.
O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team.: Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA 327: 432-441, Feb 2022.
Watson DL, Shaw PA, Petsis DT, Pickel J, Bauermeister JA, Frank I, Wood SM, Gross R.: A retrospective study of HIV pre-exposure prophylaxis counselling among non-Hispanic Black youth diagnosed with bacterial sexually transmitted infections in the United States, 2014-2019. J Int AIDS Soc 2022.
Pajon R, Paila YD, Girard B, Dixon G, Kacena K, Baden LR, El Sahly HM, Essink B, Mullane KM, Frank I, Denhan D, Kerwin E, Zhao X, Ding B, Deng W, Tomassini JE, Zhou H, Leav B, Schödel F; COVE Trial Consortium.: Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. Nat Med 2022.